Ascendis Pharma A (ASND) Free Cash Flow (2014 - 2026)
Ascendis Pharma A (ASND) posted Free Cash Flow of -$9.0 million for Q1 2026, up 92.69% sequentially from -$123.7 million in Q4 2025, and up 39.96% YoY from -$6.5 million in Q1 2025.
Ascendis Pharma A (ASND) Free Cash Flow (2014 - 2026) Analysis & Trends
Ascendis Pharma A has reported Free Cash Flow for 13 years, with the latest figure at -$9.0 million in Q1 2026.
- Quarterly Free Cash Flow rose 39.96% year-over-year to -$9.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$138.5 million (up 41.05% YoY) and the FY2025 annual result came in at -$146.4 million, up 55.26% from the prior year.
- Free Cash Flow improved to -$9.0 million in Q1 2026 per ASND's latest filing, from -$123.7 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $2.5 million in Q3 2025 and troughed at -$166.3 million in Q2 2023.
- A 5-year average of -$88.0 million and a median of -$96.5 million in 2022 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow plunged 103.56% in 2024, then surged 104.12% in 2025.
- Over 5 years, Free Cash Flow stood at -$140.7 million in 2022, then surged by 67.47% to -$45.8 million in 2023, then plunged by 103.56% to -$93.2 million in 2024, then sank by 32.79% to -$123.7 million in 2025, then jumped by 92.69% to -$9.0 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$9.0 million, -$123.7 million, and $2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | -9.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.04 Mn |
| Mar 31, 2026 | -9.04 Mn |
| Dec 31, 2025 | -123.70 Mn |
| Dec 31, 2025 | -123.70 Mn |
| Sep 30, 2025 | 2.52 Mn |
| Sep 30, 2025 | 2.52 Mn |
| Jun 30, 2025 | -8.31 Mn |
| Jun 30, 2025 | -8.31 Mn |
| Mar 31, 2025 | -15.06 Mn |
| Mar 31, 2025 | -15.06 Mn |
| Dec 31, 2024 | -93.16 Mn |
| Dec 31, 2024 | -93.16 Mn |
| Sep 30, 2024 | -61.13 Mn |
| Sep 30, 2024 | -61.13 Mn |
| Jun 30, 2024 | -65.65 Mn |
| Jun 30, 2024 | -65.65 Mn |
| Mar 31, 2024 | -110.14 Mn |
| Mar 31, 2024 | -110.14 Mn |
| Dec 31, 2023 | -45.76 Mn |
| Dec 31, 2023 | -45.76 Mn |